Literature DB >> 2499246

Monoclonal gammopathies and the kidney.

R A Kyle1.   

Abstract

The major causes of renal insufficiency, present initially in half of the patients with multiple myeloma, are "myeloma kidney" and hypercalcemia. There is no reliable evidence that the isoelectric point (pI) or the type of light chain has an important role in renal failure. Acute renal failure must be treated vigorously with appropriate fluids and electrolytes as well as hemodialysis if necessary. The benefit of plasma exchange has not been proven. Primary systemic amyloidosis or light-chain deposition disease is the usual cause of the nephrotic syndrome in patients with monoclonal gammopathy. The monoclonal gammopathies are a group of disorders that are characterized by the proliferation of plasma cells producing a homogeneous, monoclonal protein (M-protein).

Entities:  

Mesh:

Year:  1989        PMID: 2499246     DOI: 10.1146/annurev.me.40.020189.000413

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  4 in total

Review 1.  [Rapidly progressing renal insufficiency as the primary manifestation of systemic sarcoidosis].

Authors:  B Berner; E Schulz; U Wieneke; M A Reuss-Borst; B Sattler; G A Müller
Journal:  Med Klin (Munich)       Date:  1999-12-15

2.  Nephrotic syndrome and acute renal failure in non-Hodgkin lymphoplasmacytic lymphoma.

Authors:  Natasa Colović; Tatjana Terzić; Bosko Andelić; Mirjana Sretenović; Biljana Mihaljević; Jasmina Marković Lipkovski; Milica Colović
Journal:  Med Oncol       Date:  2008-01-24       Impact factor: 3.064

Review 3.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

4.  Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.

Authors:  Chung-Kuan Wu; An-Hang Yang; Hung-Chih Lai; Bing-Shi Lin
Journal:  BMC Nephrol       Date:  2017-05-25       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.